



Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. *Blood*. 2017;130(5):597-605.

In "Acknowledgments" on page 604, support from the National Institutes of Health for Jeffrey A. Zonder (grant P30 CA022453) is not acknowledged. The error has been corrected in the online version of the article.

DOI 10.1182/blood.2020005086

© 2020 by The American Society of Hematology

Downloaded from <http://ashpublications.net/blood/article-pdf/135/13/1071/1720177/blood.pdf> by guest on 08 June 2024